Evidence map›Paper›PMID 40666178›Full record

ArticleIranian journal of basic medical sciences2025

Tanshinone IIA alleviates liver fibrosis by suppressing hepatic stellate cell proliferation via ERK/cyclin D1/p-Smad3L signaling axis.

Wenjing Liao, Fang Wu, Zhiyuan Hao, Rui Ye, Chenfei Liu, Jinglei Wu, Min Wu, Xiaoman Zhou, Mingze Sun, Yuwei Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenjing LiaoSchool of Medicine, Jianghan University, Wuhan 430056, China.
Fang WuSchool of Medicine, Jianghan University, Wuhan 430056, China.
Zhiyuan HaoSchool of Medicine, Jianghan University, Wuhan 430056, China.
Rui YeSchool of Medicine, Jianghan University, Wuhan 430056, China.
Chenfei LiuSchool of Medicine, Jingchu University of Technology, Jingmen 448000, China.
Jinglei WuSchool of Medicine, Jianghan University, Wuhan 430056, China.
Min WuSchool of Medicine, Jianghan University, Wuhan 430056, China.
Xiaoman ZhouSchool of Medicine, Jianghan University, Wuhan 430056, China.
Mingze SunSchool of Medicine, Jianghan University, Wuhan 430056, China.
Yuwei LiuSchool of Medicine, Jianghan University, Wuhan 430056, China.
Meng FangSchool of Medicine, Jianghan University, Wuhan 430056, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Liver fibrosis (LF) is a critical stage in chronic liver disease progression, and effective therapeutic drugs are currently lacking. Tanshinone IIA (Tan IIA), a monomer extracted from Materials and Methods: The Results: Tan IIA markedly decreased serum levels of ALT, AST, LDH, and γ-GT. Collagen I and α-SMA were reduced, as shown by Conclusion: Tan IIA may improve LF by regulating the signaling axis of ERK/cyclin D1/p-Smad3L, thereby blocking activated HSCs in the G1 phase and inhibiting their proliferation.

Indexed as

ERK/cyclin D1/p-Smad3L – signalingHepatic stellate cellsLiver fibrosisTanshinone IIATGF-β1

Identifiers

PMID40666178
PMCPMC12258794

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.